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ABSTRACT: Teucrium yemense (Defl) (T. yemense), locally known as Reehal Fatima, is a 
medicinal plant commonly grown in Saudi Arabia and Yemen. Phytochemical investigation of 
the aerial parts of T. yemense yielded six new neoclerodane diterpenoids, namely fatimanol A-E 
(1, 2, 3, 5, 6) and fatimanone (4), and the known teulepicephin (7). As both the Teucrium genus 
and the related Lamiaceae family have previously been widely reported to possess anthelmintic 
and antimicrobial activities, the structural and biological characterisation of the seven 
diterpenoids was pursued. The structures of the new compounds were elucidated from their 2D 
NMR and MS profiles, and by comparison to related compounds. The structure of fatimanol D 
(5) was confirmed by X-ray crystallographic analysis. The new structures contribute to the 
breadth of knowledge of secondary metabolites in this genus.  
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Teucrium is a polymorphic and cosmopolitan genus of herbaceous perennial plants 
belonging to the Lamiaceae family.
1
 There are more than 340 species, including herbs, shrubs, 
and subshrubs, mainly distributed in South-East Asia, Central and South America, Mediterranean 
countries, and in the Middle East.
2
 Saudi Arabia is one of the original centers of Teucrium, 
where there currently exist at least six species.
3
 Interestingly, the genus Teucrium can be 
distinguished from other members of the Lamiaceae family, as the flowers lack the upper lip of 
the corolla.
4
 Teucrium species have been used for more than 2000 years as diuretic, diaphoteric, 
antiseptic, and antipyretic agents.
4
 Some species have also been reported to possess anti-feedant 
activities.
5,6
 In Saudi Arabia, Teucrium species have been traditionally used to treat diabetes, 
whereas, in other locales, reported activities include insecticidal, anthelmintic, analgesic, anti-
inflammatory, antioxidant, antiulcer, antispasmodic, antibacterial, and antifungal properties.
4,7−9
 
The diversity, richness, and variation of the species and the ability of the plant to produce a 
diverse array of biologically active secondary metabolites have led to much interest in this 
genus.
9
 Previous phytochemical studies revealed that the plant is a rich source of essential oils, 
diterpenoids, flavonoids, and iridoids.
10,11
 However, other compounds isolated include alkaloids, 
sterols, tannins, saponins, coumarins, and glycosides.
4,9
 
In particular, Teucrium yemense (Defl.), locally known as Reehal Fatima, is a medicinal 
plant commonly grown in Saudi Arabia and in Yemen. In these regions, the plant has long been 
used to treat kidney diseases, rheumatism and diabetes.
9,12,13
 T. yemense is an aromatic plant 
possessing sessile oblanceolate leaves and dense terminal heads of pink to scarlet to purple 
flowers.
3
 In particular, the neoclerodanes are of interest as they have been reported to encompass 
wide-ranging biological and pharmacological properties.
7,9,14−17
 While Teucrium species are 
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largely known for their essential oils, a number of novel neoclerodane diterpenoids have been 
isolated.
10,14,18,19
 
To date, the medicinal active components of T. yemense are still unknown. In the present 
study, the isolation, purification, and structural elucidation of six new neoclerodanes from T. 
yemense are reported. The compounds were tested against a range of gram-positive 
(Staphylococcus aureus and Bacillus cereus) and gram-negative (Escherichia coli and 
Pseudomonas aeruginosa) microorganisms and mammalian cytotoxicity studies were carried out 
against a human liver-derived cell line (HepG2 cell line). Furthermore, compounds 1-7 were 
assessed for anthelmintic activities against the larval schistosomula lifecycle stage of 
Schistosoma mansoni, a parasitic trematode responsible for transmitting schistosomiasis in Saudi 
Arabia and Yemen.
20
 
RESULTS AND DISCUSSION 
The dried aerial parts of the plant were defatted and extracted with MeOH. This solvent was 
evaporated and the residue was extracted with EtOAc. This extract was separated by column 
chromatography on silica gel. Repeated column chromatography and HPLC yielded seven pure 
compounds (Chart 1). Their structures were elucidated via 1D and 2D NMR and HRESIMS data. 
The absolute configurations cannot be confirmed from these data but are assumed based on 
literature precedent for related compounds.
10,21,22
 
Compound 1. The HRESIMS of 1 showed a peak at m/z 483.2222 corresponding to [M + 
H]
+
 for C24H34O10 (calcd. 483.2221) (Figure S1, Supporting Information). A peak was also 
observed at m/z 505.2040 (calcd. 505.2050), corresponding to [M + Na]
+
 for this molecular 
formula. The NMR spectra showed the appropriate numbers of 
1
H and 
13
C signals (Figures S2, 
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S3, Supporting Information). Fragment ions were observed with m/z 465 (loss of H2O, 
suggesting the presence of a hydroxy function) and m/z 423 (loss of HOAc, suggesting the 
presence of an acetoxy group). The core structure was shown to be a decalin, by a combination 
of NMR techniques (Table 1) (Figures S2-S7, Supporting Information), and related to the 
neoclerodane series of diterpenoids.
10,21,22
  
The 
1
H NMR spectrum showed a peak at  2.09 (6 H), correlating by HSQC to 
13
C 
signals at C 21.0 and 21.1 (Figures S2, S5, Supporting Information). Two ester carbonyl signals 
were observed at C 172.6 and 172.7, showing the presence of two acetate moieties (Figure S3, 
Supporting Information). HMBC data linked these to 
1
H signals at  4.65 (d, J = 12.0 Hz) and 
4.44 (d, J = 12.0 Hz) as well as to 
1
H signals at H 4.04 (d, J = 12.0 Hz) and 3.98 (d, J = 12.0 
Hz), indicating CH2OAc units in asymmetric environments. Further HMBC correlation between 
the protons at H 4.65 and 4.44 to 
13
C signals at C 74.3 (C-6), 70.5 (C-4), and 47.3 (C-10) 
confirmed the location of one acetoxymethyl unit at C-5 (Figure S6, Supporting Information). 
HMBC cross-peaks between the protons at H 4.04 and 3.98 to 
13
C signals at C 30.8 (C-11), 35.2 
(C-8), 47.3 (C-10), and C 42.8 (C-9) confirmed that the other acetoxymethyl unit was attached 
to C-9. 
The C-4 spiro-oxirane functionality was shown by the presence of a CH2 group [H 3.22 
(d, J = 4.0 Hz) and 3.01 (d, J = 4.0 Hz), C 44.3], with the small geminal coupling constant and 
shielded chemical shifts reflecting the strained three-membered ring. Relatively weak HMBC 
cross-peaks were seen between the proton at H 3.01 and C-3 (C 66.4) and C-5 (46.4), along 
with two-bond correlations between the carbon at C 70.5 and the methylene oxirane proton 
signals, confirming the C-4 spiro-oxirane moiety. The substituted 5-hydroxy-3-ethylfuran-2(5H)-
 6 
one side-chain was identified via a carbonyl at C 173.9 (C-16) and a hemiacetal carbon at C 
99.0 (HMBC to the proton at H 6.06), along with CH2 signals at C 30.8 (H 1.71) and 19.3 (H 
2.11, 2.21) and appropriate HMBC correlations. HMBC correlation between H2-20 (H 4.04 and 
3.98) and C-11 confirmed the location of this side-chain. 
The relative configurations were also established via NMR data (Figures S2-S7, 
Supporting Information). NOESY cross-peaks were observed from H-10 (H 1.66) to H-8 (H 
1.83) and to H-6 (H 3.79), confirming that all three hydrogens were cofacial and axial. The 
NOESY correlation between one of the diastereotopic CH2OAc protons (H 4.65) and H-3 (H 
4.01) also located these on the same face of the central bicycle and showed that both were also 
Chart 1. Structures of new neoclerodanes 1-6 and known analogue 7, isolated from T.  yemense. 
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axial. Thus the CH2OAc group at C-5 and H-10 are trans-diaxially disposed and the bicycle is 
confirmed as a trans-decalin. The relative configuration at the quaternary C-9 was also 
established by NOESY. Since H-8 is axial and on the -face, then CH3-17 must be equatorial and 
on the -face. A strong NOESY interaction between CH3-17 (H 0.98) and the other CH2OAc 
(H 3.98, 4.04), showed that this CH2OAc was axial on the -face and, therefore, that the 
substituted 5-hydroxy-3-ethylfuran-2(5H)-one unit was equatorial on the -face. Finally, the CH2 
of the spiro-oxirane was placed on the -face by a NOESY correlation between the oxirane CH 
(H 3.22) and H-6 (H 3.79). The configuration at C-15 could not be determined. Thus we 
propose structure 1 for fatimanol A. 
Compound 2. The HRESIMS of 2 showed a peak at m/z 401.1567, corresponding to [M + 
Na]
+
 for a molecular formula of C20H26O7 (calcd. [M + Na] 401.1576) (Figure S8, Supporting 
Information). A peak at m/z 379.1747, corresponding to [M + H]
+
 (calcd. 379.1757), confirmed 
the molecular formula. The NMR spectra showed the appropriate numbers of 
1
H and 
13
C signals 
(Figures S9, S10, Supporting Information). No MS peaks corresponding to loss of 60 Da were 
observed, suggesting the absence of acetoxy groups, 
but the sequence, m/z 379  m/z 361  m/z 343 
indicated the presence of at least two hydroxy groups. 
The NMR data (Table 1), including COSY, NOESY, 
HSQC, and HMBC spectra (Figures S9-S14, 
Supporting Information), indicated a neoclerodane 
skeleton, as for 1. However, the details of the structure, 
conformation, and configuration differ from those of 1. 
Figure 1. Views of MM2-minimised structure of 2, 
showing the positioning of the 19endo-H in the 
deshielding plane of the lactone carbonyl and the 
chair-boat conformation of the trans-decalin. 
H-19endo
H-19endo
H-19exo
H-19exo
lactone
carbonyl
H-7ax
H-7eq
H-10
H-6
CH2-18
H-2ax
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Firstly, the hemiacetal group at C-3 was shown by the chemical shift C 106.2. This may, in 
principle, be formed by cyclization of the corresponding carbonyl with a hydroxy group at C-18, 
at C-6, or at C-19. The first possibility can be dismissed, in that an oxetane moiety would be too 
strained to exist as part of a hemiacetal. Formation of a five-membered cyclic hemiacetal unit 
with the oxygen attached to C-19 was confirmed by a HMBC cross-peak between the H-19 
signal at H 4.76 and the C-3 signal at C 106.2. Thus the -CH2O- bridge spanning C-3 and C-6 is 
confirmed.  
The C-9 spiro-tetrahydrofuranone unit was established through the chemical shift of H-
12 (H 5.51), which corresponds to furanCH(R)O(C=O). The NOESY spectrum in the region H 
2.0–2.7 is unclear, precluding definite assignment of the configuration at C-9, so it is assigned by 
analogy with 1. It is notable that the diastereotopic CH2-19 protons resonate at very different 
frequencies (H 4.76 and 3.41); there must be a transannular effect which moves the signal at H 
4.76 so far downfield from the chemical shift predicted by -bond inductive effects alone. 
Examination of an MM2-minimized structure of 2 (Figure 1) provides the explanation. The 
19endo hydrogen is held rigidly in the optimal shielding plane of the magnetically anisotropic 
lactone carbonyl. Not only does this differentiate H-19endo (H 4.76) and H-19exo (H 3.41) but it 
also confirms that the lactone carbonyl is on the -face and that the absolute configuration at C-9 
is R. 
H-10 resonates at H 2.36 (dd, J = 5.0 and J = 12.5 Hz); these couplings correspond to 
3
Jax-ax and 
3
Jax-eq, respectively, with CH2-1. Thus H-10 must be axial. CH2-19 must also be axial 
to be able to form the bridge; thus the bicycle is a trans-decalin. Ring A has a chair 
conformation, confirmed by axial-axial NOESY connections from one of the CH2-18 hydrogens 
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at H 3.85 to H-10 (H 2.36) and H-2ax (H 1.49). MM2-minimization (Figure 1) of the structure 
of 2 suggests that ring B may be a distorted boat, with the “prow” and “stern” at C-7 and C-10, 
respectively. This is supported by the signal for H-6 having no coupling with J > 5 Hz, i.e. no 
trans-diaxial coupling. H-15 and H-16 of the aromatic furanyl moiety resonate at H 7.54 and 
7.60, respectively, and the shielded H-14 at H 6.50. The furanyl unit is attached to the lactone 
moiety at C-12, as confirmed by HMBC cross-peaks between H-12 (H 5.51) and C-14 (C 
109.3) and C-16 (C 141.5). Thus structure 2 is proposed for fatimanol B. 
Compound 3. The HRESIMS of 3 shows major ions at m/z 467.2272 [M + H]
+
 for a 
molecular formula C24H34O9 (calcd. 467.2281) and at m/z 489.2089 [M + Na]
+
 (calcd. 489.2101), 
confirming the molecular formula (Figure S15, Supporting Information). The NMR spectra 
showed the appropriate numbers of 
1
H and 
13
C signals (Table 1 and Figures S16, S17, 
Supporting Information). The fragmentation m/z 467  m/z 407 suggests the presence of an 
acetoxy group and the fragmentation m/z 467  m/z 449 suggests the presence of a hydroxy 
group. 
Table 1. 
1
H and 
13
C NMR Spectroscopic Data for 1-3 in Methanol-d4 [H, Multiplicity, (J (Hz))] [C, Type] 
 1 2 3 
position H C H C H C 
1 1.94 m 
1.92 m 
21.9, CH2 2.10 m 
1.58 m 
23.9, CH2 1.79 dd, 
(15.0, 2.5) 
2.13 m 
22.3, CH2 
2 2.16 m 
1.36 m 
34.5, CH2 1.65 m 
1.49 m 
33.6, CH2 2.11 m 
1.39 m 
34.4, CH2 
3 4.01 m 66.4, CH - 106.2, Cq 4.02 (dd, 
11.5, 4.5) 
66.6, CH 
4 - 70.5, Cq 2.02 d (10.0) 58.5, CH - 70.6, Cq 
 10 
5 - 46.4, Cq - 51.3, Cq - 46.4, Cq 
6 3.79 t (8.0) 74.3, CH 3.72 br s 72.2, CH 3.78 dd 
(11.5, 5.0) 
74.5, CH 
7 1.63 m 35.1, CH2 1.87 t (14) 
1.60 m 
35.1, CH2 1.66 m 
1.58 m 
35.5, CH2 
8 1.83 m 35.2, CH 2.20 m 32.7, CH 1.87 m 35.2, CH 
9 - 42.8, Cq - 53.8, Cq - 43.2, Cq 
10 1.66 m 47.3, CH 2.36 dd 
(12.5, 5.0) 
39.6, CH 2.21 dd 
(12.0, 2.0) 
47.4, CH 
11 1.71 m 30.8, CH2 2.62 dd 
(14.0, 8.5) 
2.49 dd 
(14.0, 9.0) 
45.3, CH2 1.91 dd 
(15.5, 8.5) 
1.80 dd 
(15.5, 3.5) 
40.3, CH2 
12 2.21 m 
2.11 m 
19.3, CH2 5.51 t (8.5) 73.9, CH 4.77 dd 
(8.5, 2.5) 
63.3, CH 
13 - 137.9, Cq - 126.7, Cq - 132.4, Cq 
14 7.02 s 146.7, CH 6.50 s 109.3, CH 6.42 s 109.6, CH 
15 6.06 s 99.0, CH 7.54 s 145.5, CH 7.46 s 144.7, CH 
16 - 173.9, C=O 7.60 s 141.5, CH 7.46 s 139.8, CH 
17 0.98 d (7.0) 16.5, CH3 0.97 d (6.5) 17.0, CH3 0.91 d (7.0) 16.6, CH3 
18 3.22 d (4.0) 
3.01 d (4.0) 
44.3, CH2 3.85 t (10.5) 
3.60 dd 
(10.5, 1.5) 
57.5, CH2 3.18 d (3.5) 
3.00 d (3.5) 
44.0, CH2 
19 4.65 d (12.0) 
4.44 d (12.0) 
63.7, CH2 4.76 d (8.5) 
3.41 d (8.5) 
71.6, CH2 4.71 d (12.0) 
4.43 d (12.0) 
63.8, CH2 
20 4.04 d (12.0) 
3.98 d (12.0) 
66.9, CH2 - 180.5, C=O 3.97 d (12.0) 
3.90 d (12.0) 
66.7, CH2 
1′ - 172.7, C=O   - 172.8, C=O 
2′ 2.09 s 21.1, CH3   2.10 s 21.1, CH3 
3′ - 172.6, C=O   - 172.5, C=O 
4′ 2.09 s 21.0, CH3   2.08 s 21.1, CH3 
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The combined NMR spectroscopic data of 3 showed a structure similar to that of 1, with 
structural differences in the furanyl unit and at C-12 (Figures S18-S21, Supporting Information). 
The chair-chair trans-decalin was confirmed as follows. H-10 (H 2.21) is axial, as shown by 
couplings to H-1ax (
3
Jax-ax = 12.0 Hz) and H-1eq (
3
Jax-eq = 2.0 Hz). NOESY cross-peaks between 
the H-19 resonance at H 4.71 and H-7ax (H 1.66) place this CH2OAc axial on the -face, 
confirming a trans-ring junction. H-3 is also axial, as shown by the couplings to H-2ax (
3
Jax-ax = 
11.5 Hz) and H-2eq (
3
Jax-eq = 4.5 Hz). Since H-10 and H-3 are both axial ring A must be in a chair 
conformation and the configuration at C-3 is confirmed. H-6 is axial as shown by its coupling to 
H-7ax (
3
Jax-ax = 11.5 Hz) and H-7eq (
3
Jax-eq = 5.0 Hz). H-6 also shows strong NOESY cross-peaks 
with H-10 and H-8, appropriate for cofacial axial protons. 
As for 1, the acetoxymethyl groups of 3 were located by HMBC experiments. H2-19 (H 
4.43 and 4.71) showed cross-peaks with C-4 (C 70.6), C-6 (C 74.5), and C-10 (C 47.4), in 
addition to the expected correlation with an ester carbonyl, showing that this CH2OAc group was 
at C-5. H2-20 (H 3.90 and 3.97) correlated with C-8 (C 35.2), C-10 (C 47.4), C-11 (C 40.3), 
and an ester carbonyl, linking this CH2OAc unit to C-9. The heterocyclic part is shown to be a 
furanyl moiety in 3, rather than the 5-hydroxyfuran-2(5H)-one unit of 1, by the observation of 
aromatic proton signals at H 6.42 (1 H) and 7.46 (2 H), along with 
13
C signals at C 109.6 (C-
14), 132.4 (C-13), 139.8 (C-16), and C 144.7 (C-15). The assignments were confirmed by 
HMBC and HSQC data. C-12 was shown to carry a hydroxy group, by the chemical shift of H-
12 (H 4.77), compared to H-12 (H 5.51) in 2 where the oxygen function is part of a lactone 
moiety. The absolute configuration at C-12 could not be determined spectroscopically, although 
one may speculate that it may be S, by analogy with 2. HMBC cross-peaks of H-12 with C-11, 
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C-13, C-14, and C-16 and of H2-11 with C-13 and C-20 confirmed the structure of the 9-
substituent. Weak NOESY cross-peaks were seen between H3-17 and both H2-20 and H2-11; this 
methyl group is equatorial, hence these correlations are not configurationally diagnostic for C-9. 
A strong NOESY correlation between H-10 and H-11, confirming the (9R) configuration with 
the -CH2CH(OH)furanyl moiety occupying the -face. Thus structure 3 is assigned to fatimanol 
C. 
Compound 4. For 4, the HRESIMS gave ions at m/z 485.1800 and m/z 507.1620, 
corresponding to [M + H]
+
 and [M + Na]
+
 for a molecular formula of C26H28O9 (Figure S22, 
Supporting Information). The corresponding calculated values are 485.1812 and 507.1631. The 
NMR spectra showed the appropriate numbers of 
1
H and 
13
C signals (Table 2, Figures S23 and 
S24, Supporting Information). No significant fragmentation was seen in the MS. 
 
 
Table 2. 
1
H and 
13
C NMR Spectroscopic Data for 4,5,7 in Methanol-d4 [H, multiplicity, (J (Hz))] [C, Type] 
 4 5 7 
position H C H C H C 
1 2.34 m 
1.36 ddd 
(13.0, 12.5, 
4.0) 
27.5, CH2 1.23 m 
2.10 m 
25.2, CH2 2.07 m 
2.23 m 
22.7, CH2 
2 2.00 m 
1.71 ddd, 
(13.5, 13.0, 
4.0) 
30.5, CH2 2.17 m 
1.99 m 
39.3, CH2 1.24 m 
1.45 m 
32.9, CH2 
3 3.64 dd 
(12.5, 5.0) 
77.2, CH 3.89 dd, 
(11.5, 6.0) 
75.3, CH 3.85 dd, 
(11.5, 6.0) 
73.4, CH 
4 - 77.7, Cq - 85.8, Cq - 85.6, Cq 
5 2.64 d (14.0) 55.4, CH 2.14 m 53.6, CH2 - 49.8, Cq 
6 - 213.9, C=O - 107.7, Cq - 108.6, Cq 
7 2.78 dd 
(17.0, 12.5) 
2.26 dd 
(17.0, 5.5) 
46.2, CH2 2.49 m 39.7, CH2 2.24m 
2.00 m 
37.6, CH2 
 13 
8 2.08 m 37.8, CH2 1.83 dd 
(12.5, 6.5) 
37.4, CH 2.29 m 36.3, CH 
9 - 52.5, Cq - 51.6, Cq - 50.1, Cq 
10 2.34 m 46.0, CH 1.45 m 47.8, CH 1.44 m 43.7, CH 
11 2.62 dd 
(14.0, 8.5) 
2.50 dd 
(14.0, 8.5) 
40.1, CH2 2.14 m 33.7, CH2 2.44 m 
2.22 m 
41.1, CH2 
12 5.57 t (8.5) 74.3, CH 5.46 m 73.9, CH 4.83 dd 
(8.5, 2.5) 
68.4, CH 
13 - 126.6, Cq - 126.6, Cq - 132.2, Cq 
14 6.49 d (1.0) 109.3, CH 6.48 d (1.5) 109.2, CH 6.47 s 109.6, CH 
15 7.62 br s 145.6, CH 7.54 brt (1.5) 145.7, CH 7.44 s 144.5, CH 
16 7.54 t (1.5) 141.6, CH 7.61 brd (1.0) 141.7, CH 7.46 s 139.9, CH 
17 1.00 d (7.0) 18.1, CH3 1.02 d (7.0) 17.4, CH3 0.85 d (7) 16.6, CH3 
18 4.82 d (12.5) 
4.64 d (12.5) 
65.5, CH2 4.23 d (10.0) 
3.99 d (10.0) 
74.9, CH2 4.38 d (10) 
3.99 d (10) 
75.6, CH2 
19 - - - - 4.65 d (8.5) 
4.60 d (8.5) 
63.5, CH2 
20 - 179.1, C=O - 178.9, C=O - 174.8, C=O 
1’ - 168.1, C=O - - - - 
2’ - 122.1, Cq - - - - 
3’ 7.84 d (9.0) 132.9, CH - - - - 
4’ 6.83 d (9.0) 116.2, CH - - - - 
5’ - 163.7, Cq - - - - 
6’ 6.83 d (9.0) 116.2, CH - - - - 
7’ 7.84 d (9.0) 132.9, CH - - - - 
As before, the 1D and 2D NMR data of 4 (Table 2) strongly suggested a neoclerodane 
diterpenoid structure but with two striking differences from 1-3 (Figures S25-S28, Supporting 
Information). Firstly, the C-6 chemical shift at C 213.9 indicated that the carbinol functionalities 
in 1-3 were replaced by a carbonyl group. Secondly, 
1
NMR signals were seen at H 6.83 (2 H, d) 
and 7.84 (2 H, d), indicating a para-disubstituted benzene. H-5 resonates as a doublet with 
3
J = 
14.0 Hz, thus the core of the structure is again a trans-decalin. The C-9 spiro-lactone moiety was 
demonstrated as for 2. The chemical shift of H-12 (H 5.57) is consistent with H-5 of a -lactone 
moiety and there is an HMBC connection between this proton and the lactone carbonyl carbon at 
C 179.1. The spiro-lactone was located at C-9 by HMBC connections from H-11 (H 2.50 and 
2.62) to C-10 (C 46.0); the attachment to the furanyl unit was shown by HMBC connections 
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from H-11 to C-13 (C 126.6) and from H-12 to C-13 (C 126.6), C-14 (C 109.3), and C-16 (C 
141.6). The NOESY spectrum in the H 2.0‒2.7 region is unclear, precluding assignment of the 
configuration at C-9, thus it is assigned by analogy with 1. The NOESY interaction between H3-
17 and H-11 is consistent with an equatorial orientation for the methyl group. Moreover, H-7ax 
(-face) (H 2.78) shows a trans-diaxial relationship with H-8 (H 2.08), with 
3
J7ax-8ax = 12.5 Hz, 
confirming that H-8 occupies the -face. 
In the southern zone of the structure of 4, the carbonyl group is confirmed as C-6 since 
the H2-7 signals (H 2.26 and 2.78) are significantly deshielded compared to their counterparts in 
1-3. There were confirmatory HMBC connections from C-6 (C 213.9) to H2-7 (H 2.26 and 
2.78) and to H-10 (H 2.34). H-3 (H 3.64) is -axially oriented, as shown by the coupling with 
H-2ax () (
3
Jax-ax
 
= 12.5 Hz) and H-2eq () (
3
Jax-eq
 
= 5.0 Hz), placing 3-OH equatorial on the -
face. The mutually coupled doublets at H 6.83 (2 H) and 7.84 (2 H) revealed the presence of a 4-
hydroxybenzoyl unit. This was linked as an ester to C-18 by HMBC connections from H2-18 (H 
4.64 and 4.82) to the ester carbonyl (C 168.1). A NOESY cross-peak between the signals of the 
H-18 resonance at H 4.64 and H-10 (H 2.34) confirms that the methyl 4-hydroxybenzoate unit 
is located axially on the -face, also showing that ring A occupies a chair conformation. Thus we 
propose structure 4 for fatimanone. 
Compound 5. The HRESIMS of 5 shows a major peak at m/z 387.1411, corresponding to 
[M + Na]
+
 (calcd. 387.1420) for a molecular formula of C19H24O7 (Figure S29, Supporting 
Information). Signals for 21 protons were observed in the 
1
H NMR spectrum in methanol-d4, 
showing that three hydroxy groups are present (Figure S30, Supporting Information). No 
significant fragmentation was evident in the MS. 
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The 
13
C NMR spectroscopic data of 5 (Table 2) showed signals for 19 carbons (Figure 
S31, Supporting Information). HSQC and HMBC strongly suggested that this compound had the 
neoclerodane structure but lacked C-19 (Figures S32-S35, Supporting Information). Moreover, 
the 
1
H and 
13
C NMR spectra resembled those of 2 and 4, showing the presence of the spiro-
lactone at C-9, with the adjacent furanyl moiety. H-12 resonated at H 5.46, consistent with 
furanCHO-carbonyl. This part of the structure was confirmed by HMBC cross-peaks between H-
12 and C-9 (C 51.6), C-13 (126.6), C-14 (109.2), and C-16 (141.7). H-3 (H 3.89) resonates as a 
doublet of doublets, with 
3
Jax-ax = 11.5 Hz and 
3
Jax-eq = 6.0 Hz, which indicate that it is in an axial 
position. Since H-10 is -axially oriented, HO-3 must occupy the -face. A NOESY interaction 
between H-3 and H-5 (H 2.14) showed that H-5 is also axial and , thus ring A is in a chair 
conformation and thus the bicycle is a trans-decalin. H-8 (H 1.83) resonates as a dd, with 
3
Jax-ax 
= 12.5 Hz and 
3
Jax-eq = 6.5 Hz, indicating that it is axial. Since H-8 is on the -face, ring B must 
also be a chair. The hemiacetal bridge on the -face between C-4 and C-6 was demonstrated as 
follows. The H-18 diastereotopic proton resonating at H 3.99 correlates in HMBC with C-3 (C 
75.3) and C-6 (C 107.7). The H-18 at H 4.23 also correlates with C-6 as well as C-5 (C 53.6). 
The interactions of H2-18 with C-6 confirm the presence of 
the tetrahydrofuran moiety involving both C-4 and C-6. 
The structure and configuration of 5 were 
established by single crystal X-ray crystallography (page 
41, Supporting Information). Crystallization of 5 from 
MeOH gave orthorhombic crystals, P212121, a = 6.4987(3) 
Å, b = 6.9114(3) Å, c = 41.4349(19) Å, V = 1861.05 (15) 
Figure 2. ORTEP diagram of a single molecule of 5, with water 
of crystallization, from the X-ray crystal structure determination. 
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Å
3
, Z = 4. The structure (Figure 2) contained one molecule of water of crystallization. This 
crystal structure confirmed the overall neoclerodane system, the trans-decalin configuration, the 
hemiacetal bridge and the (12S) and (8R) absolute configurations. The absolute configuration of 
compound 5 was established through the Flack parameter 0.00 (17). The structure of 5, fatimanol 
D, is thus confirmed as shown.  
Compound 6. For 6, the HRESIMS shows a sodium adduct ion at m/z 459.1619, 
corresponding to a molecular formula of C22H28O9 (calcd. [M + Na] = 459.1631) (Figure S36, 
Supporting Information). No peak was observed for [M + H]
+
 but an ion at m/z 419 corresponds 
to loss of water from the protonated molecular ion and indicates the presence of a hydroxy 
group. Broad signals for three hydroxy group protons are present at H 3.1, 4.5, and 4.7 in the 
1
H 
NMR spectrum of 6 in CDCl3 (Figure S37, Supporting Information). 
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Collectively, the NMR data of 6 (Table 3) 
(Figures S37-S42, Supporting Information) 
resembled those of 5, but with H-5 substituted by 
an acetoxymethyl group. As usual, connectivity 
around the decalin was established by a 
combination of COSY, HSQC, and HMBC 
spectra (Figures S39-S42, Supporting 
Information). H-3 (H 3.94) is axial, as shown by 
3
Jax-ax = 11.5 Hz to the adjacent H-2ax. H-3 also 
showed NOESY interactions with H-2eq (H 
1.50) and H-1ax (H 2.23); the latter is only 
possible when H-1ax is cofacial with H-3ax and 
thus ring A is in a chair conformation. 
The -CH2OAc group is shown by HMBC 
connections between H2-19 (H 4.83 and 4.92) and the ester carbonyl (C 171.5). Further HMBC 
cross-peaks to the signals for C-4 (C 85.7), C-6 (108.0), and C-10 (50.3) show that this acetoxy-
methyl group is at C-5. A NOESY interaction between H2-19 and H-1ax confirmed that the 
acetoxymethyl group is -axially oriented, thus ring A occupies a chair conformation. This 
implies that H-10 is -axially oriented, a conclusion that was confirmed by coupling with H-1. 
HMBC cross-peaks from H-18 at H 4.40 to C-3 (C 72.5) and C-6 (108.0) show that CH2-18 is 
attached to C-4 with the hemiacetal functionality at C-6. This C-18 proton also shows a NOESY 
association with H-10 (H 1.77), indicating that CH2O-18 occupies the -face and that C-18 and 
Table 3. 
1
H and 
13
C NMR Spectroscopic Data for 
6 in CDCl3 [H, Multiplicity, (J (Hz)] [C, Type] 
position H C 
1 2.23 m 
1.90 m 
21.8, CH2 
2 1.23 m 
1.50 m 
32.1, CH2 
3 3.94 dd (11.5, 
6.0) 
72.5, CH 
4 - 85.7, Cq 
5 - 50.4, Cq 
6 - 108.0, Cq 
7 2.23 m 
1.93 m 
37.1, CH2 
8 1.88 m 36.9, CH 
9 - 53.3, Cq 
10 1.77 m 50.3, CH 
11 2.47 m 
2.34 m 
42.3, CH2 
12 5.40 t (8.5) 71.8, CH2 
13 - 124.9, Cq 
14 6.39 s 108.1, CH 
15 7.44 s 144.4, CH 
16 7.47 s 139.9, CH 
17 1.05 d (7.0) 16.0, CH3 
18 4.40 d (10.0) 
4.02 d (10.0) 
74.5, CH2 
19 4.92 d (8.5) 
4.83 d (8.5) 
62.1, CH2 
20 - 176.8, C=O 
1’ - 171.5, C=O 
2’ 2.07 s 21.4, CH3 
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the hemiacetal –O– at C-6 are both pseudoaxial. Thus, ring B adopts a chair conformation and 
forms part of a trans-decalin core. 
In the spiro--lactone unit, H-12 resonates at H 5.40 and H2-11 at H 2.34 and 2.47. 
HMBC cross-peaks between H-12 and C-14 (C 108.1), C-13 (124.9), and C-16 (139.9) confirm 
that the furanyl moiety is joined to the lactone unit. HMBC cross-peaks between H-11 (H 2.47) 
and C-8 (C 36.9) and C-10 (50.3), between H-11 (H 2.34) and C-10 (C 50.3), and between H-
10 (H 1.77) and C-20 (C 176.8) locate the spiro-lactone moiety at C-9. The configuration at this 
center is the same as in 1-5, as indicated by a NOESY correlation between H-11 (H 2.34) and H-
10 (H 1.77). NOESY correlations from H-12 (H 5.40) to H-10 (H 1.77) and H-1ax (H 2.23), 
are consistent with a (12S) absolute configuration. The signals for H-12 and H3-17 (H 1.05) are 
appropriately unconnected in NOESY. Interestingly, H2-19 resonate at unusually low field (H 
4.83 and 4.92), due to their location in the deshielding plane of the anisotropic spiro-lactone 
carbonyl (vide supra). The (8R) absolute configuration is assigned by analogy with 1-5. Thus we 
assign structure 6 for fatimanol E. 
Compound 7. The HRESIMS of 7 shows a sodium adduct ion at m/z 417.1513 (calcd. 
417.1525) for a molecular formula of C20H26O8 (Figure S43, Supporting Information). The 
abundant ion at m/z 377 corresponds to loss of H2O from the protonated molecular ion, 
indicating at least one hydroxy group. The 
1
H NMR data (Table 2) contain signals for 26 protons 
and the 
13
C spectrum contained 20 discrete peaks including a typical ester/lactone carbonyl (C 
174.8) (Figures S44, S45, Supporting Information). As for 1-6, the HMBC connectivity showed 
the neoclerodane skeleton (Figures S46-S48, Supporting Information). H-3 is again shown by the 
values of the coupling constants to H-2ax (
3
Jax-ax 11.5 Hz) and H-2eq (
3
Jax-ax 6.0 Hz) to be -
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axially oriented. The acetal bridge between C-4 and C-6 is shown by HMBC connections 
between H2-18 (H 3.99 and 4.38) and C-3 (C 73.4), C-4 (85.6), C-5 (49.8), and C-6 (108.6), the 
latter being particularly diagnostic of the closure of the cyclic hemiacetal moiety. A NOESY 
interaction between H-18 (H 4.38) and H-10 (H 1.44) places both C-18 and H-10 axial on the 
-face and assigns the signal at H 4.38 as H-18endo. 
Rather than forming a spiro-lactone, as in 2, 4-6, C-20 forms a bridging lactone with 
CH2O-19, as shown by an HMBC connection between H2-19 (H 4.60 and 4.65) and C-3 (C 
73.4), C-4 (85.6), C-5 (49.8) and C-6 (108.6), the latter being particularly diagnostic of the 
closure of the hemiacetal ring. Since a NOESY 
interaction between H-10 and H-11 (H 2.44) shows 
that CH2-11 must be on the -face, C-20 must be on 
the -face. C-19 must also be on the -face (Figure 
3). Thus, 7 contains a trans-decalin moiety. The 
presence of the furan-CH(OH)-CH2- unit at C-9 is 
confirmed via the HMBC cross-peaks of H2-11 with 
C-10 (C 43.7), C-12 (68.4), C-13 (132.2), and C-20 
(174.8). H-12 (H 4.83) resonates at a chemical shift 
appropriate for furanCHR(OH), rather than an ester 
function, and shows HMBC cross-peaks with C-9 
(C 50.1), C-13 (132.1), C-14 (109.6), and C-16 
(139.9). It was not possible to determine the 
configuration at C-12.  
Figure 3. Upper: View (hydrogens omitted) of MM2-
minimised structure of 7, showing the hemiacetal and 
lactone bridges. Lower: Coplanarity of C-6, C-7, C-8 
and CH3-17 in MM2-minimised structure of 7. 
Hemiacetal
bridge
Lactone
bridge
C-8
C-7
C-6
CH3-17
 20 
CH3-17 (H 0.85) is attached at C-8 (C 36.3), as shown by HMBC cross-peaks to C-7 (C 37.6), 
C-8 (36.3), and C-9 (50.1), in addition to a weak interaction with C-6 (C 108.6). Examination of 
an MM2-minimized model of 7 suggests that CH3-17, if equatorial and , should make the (C-
17)-(C-8)-(C-7)-(C-6) unit antiperiplanar and consistent with a larger 
4
JH-C (Figure 3). Thus, 
structure 7 is assigned to teulepicephin. This compound was isolated previously
14
 from Teucrium 
lepicephalum and T. buxifolium but only characterized as the 3-O-acetate acetyl derivative. 
Li et al. have recently published a comprehensive review of clerodanes and related 
compounds, including cataloguing their structures and biological activities.
23
 The C-4 spiro-
oxirane moiety (in 1 and 3) is present in a number of related natural products, including 
clerodanes isolated from Polyalthia longifolia var. pendula
24
 and Teucrium polium,
25
 whereas 
the 5-hydroxy furan-2(5H)-one feature (C-13, C-14, C-15, C-16) seen in 1 is less common, being 
exemplified by salvidin B from Salvia divinorum
15
 and rumphioside A from Tinospora 
rumphii.
26
 The lactol functionality in 2 is rare, having only been reported in teupestalin A
27
 and 
four compounds from Teucrium species.
6,28
 Thus, the new compounds contain some features 
which are unusual in naturally occurring clerodanes. 
Biological evaluation 
Compounds 1-7 were evaluated for 
antimicrobial activity against the bacteria 
Escherichia coli, Pseudomonas aeruginosa, 
Staphylococcus aureus, Mycobacterium 
smegmatis and the yeast Candida albicans. 
No significant inhibitory activity was seen for 
Table 4. Stimulation of the Growth of E. coli by 1 
and 3. Data Represent OD600nm of Wells as 
Percentages of No-drug Controls. 
 Conc. 
(M) 
OD600 as percentage of no-
drug control 
1 1037 234  52 
519 273  29 
259 226  73 
130 154  29 
65 130  4 
3 1073 200  35 
536 238  67 
268 273  53 
134 122  32 
67 129  16 
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any compound against any of the five microorganisms (Figure S49, Supporting Information). 
However, 1 and 3 appeared to show concentration-related stimulation of the growth of E. coli at 
concentrations >100 M (Table 4). 
 No cytotoxic activity was seen against HepG2 human hepatocellular carcinoma cells 
for 1-7 at concentrations <200 M, using the MTT assay (Figure S50, Supporting Information). 
Although extracts of plants in the Teucrium genus and the related Lamiaceae family have 
been widely reported to exhibit anthelmintic activities, the compound(s) responsible for these 
biological activities are still unclear.
9,29
 Therefore, 1-7 were assessed for anthelmintic activities 
(phenotypes and motility) against the larval schistosomula lifecycle stage of Schistosoma 
mansoni. No activity was observed at 10 M.30 (Figures S51-S53, Supporting Information). 
In this paper, we report the isolation and structural elucidation of six new neoclerodanes 
and a neoclerodane new to T. yemense. The new compounds combine structural features 
common in clerodanes with some of the more rare features. Cytotoxicity towards mammalian 
tumor cells has been reported for several clerodanes,
23
 including the cesearupestrins.
31
 
Antifungal and antibacterial activities have also been reported for some examples but these 
clerodanes often have a narrow spectrum of activity.
23
 However, 1-7 were shown to be devoid of 
such activity. Thus, the identification of the new neoclerodanes 1-6 contributes to the knowledge 
and understanding of the diversity of this important group of diterpenoids. 
EXPERIMENTAL SECTION 
General Experimental Procedures. The mp was measured on a Buchi Melting Point B-
545 apparatus. The optical rotation was recorded on a Jasco Polarimeter P-2000 and UV was 
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recorded on a UV.1601 PC (Shimadzu) instrument. IR spectra were recorded on a Perkin-Elmer 
FTIR 600 series spectrometer. The 1D and 2D NMR spectra (
1
H, COSY, NOESY, HSQC, and 
HMBC) were performed using Bruker spectrometers (500 MHz for 
1
H and 175 MHz for 
13
C 
NMR spectra). Conventional pulse sequences were used for COSY, HSQC, and HMBC. 
Chemical shift values are reported in  (ppm), relative to internal TMS or residual solvent peak; 
coupling constants (J) are in Hertz (Hz). Ultra-high accuracy mass analysis was performed on a 
Nano-Flow (Triversa Nanomate; Advion Biosciences Limited, Norfolk, UK) linear trap 
quadrupole Fourier Transformation Ion Cyclotron Resonance Mass Spectrometry Ultra (FT-ICR-
MS). Samples were reconstituted in HPLC-grade MeOH / ultra-pure water (7:3, 100 L). 
Samples were vortexed and were centrifuged for 4 min at 13,000 rpm at 0 ºC. Supernatant (20 
L) was transferred to a clean well on a 128-well plate. Sample (13 L) was injected by the 
nano-flow injection system, with an aliquot (5 L) delivered to the ICR cell. Gas pressure was 
maintained at 0.5 psi with an applied voltage of 1.5 KV to maintain a consistent current of 60-
120 nA. When operating in narrow SIM mode, the resolution was 100,000 and the scan window 
30 m/z. Each scan was acquired in 60 sec. Column chromatography used normal-phase silica gel 
(Merck; 230-400 m). HPLC was performed on a Shimadzu system (Kyoto, Japan), consisting 
of two LC-6AD Semi-Preparative Solvent Delivery pumps coupled with Rheodyne manual 
injector, communications bus module CBM-20A, a multi-wavelength photo-diode array detector 
(SPD-M20A), FRC-10A fraction collector, all connected to a computer system with Intel Core 
DUO with Microsoft XP and Shimadzu’s LC solution software. It was fitted with two columns, 
Shim-pack PREP-ODS (H) Kit (A) 250 mm × 4.6 mm I.D., 5 m particles (B) 250 mm × 20 mm 
I.D. Analytical HPLC was performed using the column under gradient conditions with mobile 
phase (MeCN / H2O) programmed linearly to 100% MeCN during 35 min at 1.0 mL min
-1
. The 
 23 
UV detection wavelengths were 210 and 254 nm. The chromatographic separation HPLC was 
performed using column and preparative HPLC conditions as for analytical HPLC, except the 
flow rate was 20 mL min
-1
. 
Plant Material. Teucrium yemense (Defl.) was collected in February, 2014, from Aqabat 
Al-Abna, Baljurashi, Saudi Arabia, and was identified by taxonomist Dr. M. Yusuf, College of 
Pharmacy, King Saud University (KSU), Riyadh, Saudi Arabia. A voucher specimen (# 15292) 
has been deposited at the herbarium of the College of Pharmacy, KSU.  
Extraction and Isolation. Dried and finely powdered aerial parts of T. yemense were 
defatted with n-hexane and extracted with MeOH. The EtOAc-soluble part of the MeOH extract 
was separated by column chromatography on silica gel to afford several fractions. Two polar 
fractions were subjected to repeated column chromatography and HPLC on an RP18 semi-
preparative column, resulting in the isolation of 1-7 (Page 5, Supporting Information). 
Fatimanol A (1): colorless gum; []21D +111 (0.055, MeOH); UV (MeOH) max(log ) 
238 (3.37), 266 (3.22) nm; IR (KBr) max 3412, 3004, 1730, 1716, 1420, 1362, cm
-1
; 
1
H and 
13
C 
NMR, see Table 1; HMBC (Figure S6, Supporting Information), HRESIMS m/z [M + Na]
+
 
505.2050, calcd. for C24H34O10Na, 505.2040. 
Fatimanol B (2): colorless gum; []21D -14.6 (0.015, MeOH); UV (MeOH) max(log ) 
223 (1.20) nm; IR (KBr) max 3602, 3404, 1714, 1423, 1363 cm
-1
; for 
1
H and 
13
C NMR, see 
Table 1; HMBC (Figure S13, Supporting Information), HRESIMS m/z [M + Na]
+ 
401.1567, 
calcd. for C20H26O7Na, 401.1576. 
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Fatimanol C (3): colorless gum; []21D +26.4 (0.21, MeOH); UV (MeOH) max(log ) 
226 (2.53) nm; IR (KBr) max 3478, 2937, 1739, 1716, 1374, 1245 cm
-1
; for 
1
H and 
13
C NMR, 
see Table 1; HMBC (Figure S20, Supporting Information), HRESIMS m/z [M + Na]
+ 
489.2089, 
calcd. for C24H34O9Na, 489.2101. 
Fatimanone (4): colorless gum; []21D -25.7 (0.173, MeOH); UV (MeOH) max(log ) 
222 (3.32), 269 (4.49), 329 (3.03) nm; IR (KBr) max 3622, 2321, 1732, 1714, 1592, 1214 cm
-1
; 
for 
1
H and 
13
C NMR, see Table 1; HMBC (Figure S27, Supporting Information), HRESIMS m/z 
[M + Na]
+ 
m/z 507.1620, calcd. for C26H28O9Na, m/z 507.1631. 
Fatimanol D (5): white crystals; mp 89-91 °C; []21D -34.2 (0.152, MeOH); UV (MeOH) 
max(log ) 232 (3.27) nm; IR (KBr) max 3622, 3004, 1733, 1714, 1589, 1215 cm
-1
; for 
1
H and 
13
C NMR, see Table 2; HMBC (Figure S34, Supporting Information), HRESIMS [M + Na]
+ 
m/z 
387.1411, calcd. for C19H24O7Na, m/z 387.1420. 
Single crystals of 5 were obtained by slow evaporation from MeOH at room temperature. 
Data were collected on a Bruker APEX-II D8 Venture area diffractometer, equipped with 
graphite monochromatic CuK radiation, λ = 1.54178 Å at 100 (2) K. Cell refinement and data 
reduction were carried out by Bruker SAINT. SHELXT
32,33
 was used to solve the structure. The 
final refinement was carried out by full-matrix least-squares techniques with anisotropic thermal 
data for non-hydrogen atoms on 𝐹. CCDC 1473246 contains the supplementary crystallographic 
data for this compound, which can be obtained free of charge from the Cambridge Crystallographic 
Data Centre via www.ccdc.cam.ac.uk/data_request/cif 
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Fatimanol E (6): colorless gum; []21D +15.2 (0.20, MeOH); UV (MeOH) max(log ) 
231 (2.69) nm; IR (KBr) max 3446, 2969, 1761, 1742, 1705, 1244 cm
-1
; for 
1
H and 
13
C NMR, 
see Table 2; HMBC (Figure S41, Supporting Information), HRESIMS [M + Na]
+ 
m/z 459.1619, 
calcd. for C22H28O9Na, m/z 459.1631. 
Teulepicephin (7): colorless gum; []21D +3.4 (0.35, MeOH); UV (MeOH) max(log ) 
232 (3.09) nm; IR (KBr) max 3602, 3004, 1714, 1362,1222 cm
-1
; for 
1
H and 
13
C NMR, see Table 
2; HMBC (Figure S47, Supporting Information), HRESIMS [M + Na]
+ 
m/z 417.1513, calcd. for 
C22H30O10Na, m/z 417.1525. 
Compound Handling for Bioassays. Compounds 1-7 in DMSO (Fisher Scientific, 
Loughborough, UK) at concentrations of 10 mM and 1.6 mM were stored at -20°C.  
Antimicrobial Assay. Bacterial suspensions were prepared by direct colony suspension. 
They were incubated overnight at 37°C in a temperature-controlled orbital shaker and were 
standardised to a McFarland standard value of 0.5 (1 × 10
8
 cfu mL
-1
) using a 
spectrophotometer.
34
 Nutrient broth (190 L) was added to each well in the 96-well plate. 
Further broth (160 L) was added to wells A1-12, followed by test solution (40 L). The sample 
was mixed, an aliquot (200 L) was taken and added to each wells through to row E. Rifampicin 
(61 M, control) was added to row F. The wells in rows G and H were left untreated. 
Standardised overnight culture (10 L; 1 × 107 cfu mL-1) was added to rows A-G to provide a 
final in-well concentration of 5 × 10
5 
cfu mL
-1
. Plates were incubated in a Hidex Sense Plate 
Reader (LabLogic, Sheffield UK) at 37C and shaken at 300 rpm for 24 h. The optical density 
(OD) was measured at 600 nm every 20 min for 24 h. 
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MTT Cytotoxicity Assay. HepG2 cells (Sigma Aldrich, Gillingham, UK) were seeded at a 
density of 2.0  104 per well in a 96-well microtiter plate (Fisher Scientific, Loughborough, UK) 
in modified BME medium (50 L; containing 1% antibiotic / mycotic (Sigma Aldrich, 
Gillingham, UK), 1% 200 mM L-Gln (Gibco, Paisley, UK), 1% MEM non-essential amino acid 
solution (Gibco, Paisley, UK) and 10% fetal bovine serum (Gibco, Paisley, UK). Cells were 
incubated in a humidified atmosphere containing 5% CO2 at 37C for 24 h prior to addition of 
compounds. Compounds were added to achieve final concentrations of 100-0.01 M. After 20 h 
incubation, thiazolyl blue tetrazolium bromide [MTT; 5.0 L, 12 mM (Sigma Aldrich, 
Gillingham, UK)] was added to each well. The culture medium was then removed gently after 4 
h incubation. DMSO: isopropanol (1:1, 50 L) was added and the plate was incubated for 15 
min. The plate was agitated to ensure complete dissolution of formazan crystals and absorbance 
measurements (570 nm) were obtained at using a POLARstar Omega BMG Labtech v 1.02 plate 
reader. Blank wells, as well as positive (1% DMSO) and negative (1% Triton X-100, Fisher 
Bioreagents, Loughborough, UK) controls were incorporated in each plate.  
Each data point represents a mean of three data sets (Supporting Information), with 
standard error presented. All absorbance readings were adjusted for background absorbance 
(eight blank wells per plate). Three positive (DMSO) and negative control (Triton X-100) wells 
were included, (1% final concentration) and gave absorbance readings of 0.578 (SE 0.031) and 
0.024 (SE 0.004), respectively. All values have been adjusted for the background absorbance on 
the plate. The average (AVE) absorbance and standard deviation (SD) were calculated for each 
compound at each concentration. 
 27 
Schistosoma mansoni Anthelmintic Screening. Potential anti-schistosomal effects of 1-
7 (10 M final concentration) were assessed on 24 h cultured schistosomula, according to the 
method described by Paveley.
30
 Compounds 1-7 were prepared for screening in a 384-well plate 
(Perkin Elmer, MA, USA), where solutions (1.6 mM, 0.5 L) were wet stamped using the 
Biomek NX
P
 liquid handling platform into Basch medium (20 L).35 Controls were also wet 
stamped in the same manner, allowing for 16 wells each of DMSO (negative control) and 
Auranofin (Sigma, cat# A6733, positive control). Basch medium (60 L), containing ~120 
mechanically transformed schistosomula, were distributed into each treated well using a 
WellMate (Thermo Scientific, Loughborough, UK). The plate was incubated at 37C for 24 h in 
a humidified atmosphere containing 5% CO2. The plate was imaged using an ImageXpressXL 
high content imager (Molecular Device, UK) and further analyzed for effects on motility and 
phenotype, as previously reported by Paveley.
30
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